Literature DB >> 28835615

Logic programming reveals alteration of key transcription factors in multiple myeloma.

Bertrand Miannay1,2, Stéphane Minvielle2,3, Olivier Roux1, Pierre Drouin1, Hervé Avet-Loiseau4, Catherine Guérin-Charbonnel2,5, Wilfried Gouraud2,5, Michel Attal6, Thierry Facon7, Nikhil C Munshi8,9, Philippe Moreau2,3, Loïc Campion2,5, Florence Magrangeas10,11, Carito Guziolowski12.   

Abstract

Innovative approaches combining regulatory networks (RN) and genomic data are needed to extract biological information for a better understanding of diseases, such as cancer, by improving the identification of entities and thereby leading to potential new therapeutic avenues. In this study, we confronted an automatically generated RN with gene expression profiles (GEP) from a cohort of multiple myeloma (MM) patients and normal individuals using global reasoning on the RN causality to identify key-nodes. We modeled each patient by his or her GEP, the RN and the possible automatically detected repairs needed to establish a coherent flow of the information that explains the logic of the GEP. These repairs could represent cancer mutations leading to GEP variability. With this reasoning, unmeasured protein states can be inferred, and we can simulate the impact of a protein perturbation on the RN behavior to identify therapeutic targets. We showed that JUN/FOS and FOXM1 activities are altered in almost all MM patients and identified two survival markers for MM patients. Our results suggest that JUN/FOS-activation has a strong impact on the RN in view of the whole GEP, whereas FOXM1-activation could be an interesting way to perturb an MM subgroup identified by our method.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28835615      PMCID: PMC5569101          DOI: 10.1038/s41598-017-09378-9

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  50 in total

1.  KEGG: kyoto encyclopedia of genes and genomes.

Authors:  M Kanehisa; S Goto
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element.

Authors:  Marc R Mansour; Brian J Abraham; Lars Anders; Alla Berezovskaya; Alejandro Gutierrez; Adam D Durbin; Julia Etchin; Lee Lawton; Stephen E Sallan; Lewis B Silverman; Mignon L Loh; Stephen P Hunger; Takaomi Sanda; Richard A Young; A Thomas Look
Journal:  Science       Date:  2014-11-13       Impact factor: 47.728

3.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

4.  Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines.

Authors:  M Hallek; C Neumann; M Schäffer; S Danhauser-Riedl; N von Bubnoff; G de Vos; B J Druker; K Yasukawa; J D Griffin; B Emmerich
Journal:  Exp Hematol       Date:  1997-12       Impact factor: 3.084

Review 5.  The genetic architecture of multiple myeloma.

Authors:  Gareth J Morgan; Brian A Walker; Faith E Davies
Journal:  Nat Rev Cancer       Date:  2012-04-12       Impact factor: 60.716

6.  Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.

Authors:  H Avet-Loiseau; B G M Durie; M Cavo; M Attal; N Gutierrez; J Haessler; H Goldschmidt; R Hajek; J H Lee; O Sezer; B Barlogie; J Crowley; R Fonseca; N Testoni; F Ross; S V Rajkumar; P Sonneveld; J Lahuerta; P Moreau; G Morgan
Journal:  Leukemia       Date:  2012-10-03       Impact factor: 11.528

7.  Interleukin-6-induced inhibition of multiple myeloma cell apoptosis: support for the hypothesis that protection is mediated via inhibition of the JNK/SAPK pathway.

Authors:  F H Xu; S Sharma; A Gardner; Y Tu; A Raitano; C Sawyers; A Lichtenstein
Journal:  Blood       Date:  1998-07-01       Impact factor: 22.113

8.  Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma.

Authors:  Klaus Podar; Marc S Raab; Giovanni Tonon; Martin Sattler; Daniela Barilà; Jing Zhang; Yu-Tzu Tai; Hiroshi Yasui; Noopur Raje; Ronald A DePinho; Teru Hideshima; Dharminder Chauhan; Kenneth C Anderson
Journal:  Cancer Res       Date:  2007-02-15       Impact factor: 12.701

9.  Proper evaluation of alignment-free network comparison methods.

Authors:  Ömer Nebil Yaveroğlu; Tijana Milenković; Nataša Pržulj
Journal:  Bioinformatics       Date:  2015-03-24       Impact factor: 6.937

10.  PID: the Pathway Interaction Database.

Authors:  Carl F Schaefer; Kira Anthony; Shiva Krupa; Jeffrey Buchoff; Matthew Day; Timo Hannay; Kenneth H Buetow
Journal:  Nucleic Acids Res       Date:  2008-10-02       Impact factor: 16.971

View more
  8 in total

1.  Proteomics Versus Clinical Data and Stochastic Local Search Based Feature Selection for Acute Myeloid Leukemia Patients' Classification.

Authors:  Lokmane Chebouba; Dalila Boughaci; Carito Guziolowski
Journal:  J Med Syst       Date:  2018-06-04       Impact factor: 4.460

2.  Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma.

Authors:  Chunyan Gu; Xuefang Jing; Carol Holman; Ramakrishna Sompallae; Fenghuang Zhan; Guido Tricot; Ye Yang; Siegfried Janz
Journal:  BMC Cancer       Date:  2018-11-21       Impact factor: 4.430

3.  Prediction and prognostic significance of BCAR3 expression in patients with multiple myeloma.

Authors:  Weilong Zhang; Yuansheng Lin; Xiaoni Liu; Xue He; Ye Zhang; Wei Fu; Zuozhen Yang; Ping Yang; Jing Wang; Kai Hu; Xiuru Zhang; Weiyou Liu; Xiaoliang Yuan; Hongmei Jing
Journal:  J Transl Med       Date:  2018-12-18       Impact factor: 5.531

4.  High expression of CHML predicts poor prognosis of multiple myeloma.

Authors:  Weilong Zhang; Ling Cao; Xiaoni Liu; Xue He; Ye Zhang; Zuozhen Yang; Ping Yang; Jing Wang; Kai Hu; Xiuru Zhang; Weiyou Liu; Xiaoliang Yuan; Hongmei Jing
Journal:  J Cancer       Date:  2019-10-15       Impact factor: 4.207

5.  Current perspectives on interethnic variability in multiple myeloma: Single cell technology, population pharmacogenetics and molecular signal transduction.

Authors:  Manav Gandhi; Viral Bakhai; Jash Trivedi; Adarsh Mishra; Fernando De Andrés; Adrián LLerena; Rohit Sharma; Sujit Nair
Journal:  Transl Oncol       Date:  2022-09-11       Impact factor: 4.803

6.  Constraints on signaling network logic reveal functional subgraphs on Multiple Myeloma OMIC data.

Authors:  Bertrand Miannay; Stéphane Minvielle; Florence Magrangeas; Carito Guziolowski
Journal:  BMC Syst Biol       Date:  2018-03-21

7.  Abnormal PTBP1 Expression Sustains the Disease Progression of Multiple Myeloma.

Authors:  Hua Bai; Bing Chen
Journal:  Dis Markers       Date:  2020-06-18       Impact factor: 3.434

Review 8.  The Role of AP-1 Transcription Factors in Plasma Cell Biology and Multiple Myeloma Pathophysiology.

Authors:  Fengjuan Fan; Klaus Podar
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.